The landscape of diabetes treatment and obesity management in India is evolving rapidly, with Mounjaro® India gaining attention among healthcare professionals. A recent tirzepatide survey conducted by SPER Market Research reveals how physicians are responding to this novel GLP-1 receptor agonist.

This comprehensive physician insights study involved 105 Indian doctors, including endocrinologists, diabetologists, and internal medicine specialists. With an average of 14.6 years of experience and over 140 patient interactions weekly, their perspectives offer a credible snapshot of Indian healthcare trends.

Rising Awareness of Mounjaro® in India
According to the tirzepatide survey, 85% of physicians are aware of Mounjaro®, and 72% correctly identify its dual GIP + GLP-1 mechanism. While only 31% currently prescribe it, another 24% plan to begin within six months. The drug is primarily used for diabetes treatment in patients with obesity, where it shows superior outcomes in weight reduction (78%) and glycemic control (65%).

Barriers to Broader Adoption
Despite growing interest, the Mounjaro India uptake remains limited. The SPER Market Research study highlights key barriers: high cost (83%), limited availability (62%), and lack of inclusion in Indian treatment guidelines (47%). These challenges restrict usage to fewer than 10% of eligible patients.

Competitive Edge in Obesity Management
Physicians perceive Mounjaro® as more effective than alternatives like Ozempic® and Saxenda®, especially in weight maintenance and patient satisfaction. However, cost-effectiveness remains a concern, with 45% rating it less favorable than existing therapies.

Future Outlook
Encouragingly, 65% of physicians expect moderate-to-strong growth in Mounjaro® adoption over the next year. Key drivers include affordability, broader access, and real-world Indian data. As Indian healthcare trends shift toward advanced therapies, Mounjaro® is poised to become a cornerstone in obesity management and diabetes treatment.

For a detailed breakdown of this tirzepatide survey, visit SPER Market Research and explore how physician insights are shaping the future of Mounjaro India.